Literature DB >> 27400894

Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?

Sanjay Kaul1.   

Abstract

Entities:  

Keywords:  clinical trial; diabetes mellitus; mortality

Mesh：

Substances：

Year:  2016        PMID： 27400894     DOI： 10.1161/CIRCULATIONAHA.116.022537

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

Review 1.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

2.  Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis.

Authors:  Awadhesh Kumar Singh; Ritu Singh
Journal:  Indian J Endocrinol Metab       Date:  2017 Jan-Feb

3.  Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.

Authors:  Hao Zhou; Shuyi Wang; Pingjun Zhu; Shunying Hu; Yundai Chen; Jun Ren
Journal:  Redox Biol       Date:  2017-12-30       Impact factor: 11.799

Review 4.  Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis.

Authors:  Viraj Ramesh Suvarna
Journal:  Perspect Clin Res       Date:  2021-01-08

5.  Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development.

Authors:  Jennifer Clark; Natalia Muhlemann; Fanni Natanegara; Andrew Hartley; Deborah Wenkert; Fei Wang; Frank E Harrell; Ross Bray
Journal:  Ther Innov Regul Sci       Date:  2022-01-03       Impact factor: 1.778
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.